NCT06786208

Real-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure

Real-world Study of Sunvozertinib Treatment in Locally Advanced or Metastatic EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 55 (estimated)
• Sponsor: Henan Cancer Hospital · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Observe the efficacy and safety of sunvozertinib in the real world in the treatment of EGFRm aNSCLC patients with previous EGFR-TKI treatment

Detailed description

Locally advanced or metastatic NSCLC with EGFR-sensitive mutations who have been previously treated with EGFR-TKIs and PD for last therapy can be involved in this study. Investigators will assess patients whether to be suitable for sunvozertinib treatment. And this study will evaluate the safety and efficacy.

Conditions

• Non Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Sunvozertinib	sunvozertinb, a EGFR-TKI, 300mg QD oral

Timeline

• Start date: 2025-02-01
• Primary completion: 2025-12-30
• Completion: 2027-06-30
• First posted: 2025-01-22
• Last updated: 2025-01-22

Locations

1 site across 1 country: China